EXCLUSIVE- ISRAEL'S TEVA, UK'S MYLAN, INDIA'S SUN PHARMACEUTICAL EYE PFIZER'S BRAZILIAN GENERIC DRUG VENTURE TEUTO, SOURCES SAY. » Read More
Stocks rallied to the finish line Monday after a wobbly morning as a CIT deal to avert bankruptcy and strong earnings gave investors cause for optimism.
A strong start for stocks began to peter out Monday, though CIT continued to rally.
Stocks opened higher Monday as investors were cheered by news of a deal that will avoid bankruptcy for commercial lender CIT Group and a better-than-expected start the earnings season.
Futures indicated a positive open for Wall Street Monday as investors were cheered by news of a deal that will avoid bankruptcy for commercial lender CIT Group.
The Food and Drug Administration today announced that Teva Pharmaceutical Industries is voluntarily recalling two lots of the anesthetic Propofol because there are higher levels of potentially fatal endotoxins...Propofol is the same drug that was reportedly found in Michael Jackson’s house.
Carl Icahn and all of the Elanians should be happy. Biogen Idec today reported encouraging trends regarding its all-important multiple sclerosis drug Tysabri.
Two congressmen who are tackling the new healthcare legislation don't want to go too far in implementing potential solutions, however.
Man, time flies. I can't believe almost a year has passed since the incident at ICAD. That's the big Alzheimer's Disease scientific research conference that was held in Chicago in late July last year. This year, it's in Vienna and it's going on right now.
A full-blown swine flu pandemic hitting the UK could see one in four employees forced to stay home at a cost of 1.5 billion pounds ($2.4 billion) each day, new research suggests.
For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.
I was wrong. I'd blogged a few times that I thought the FDA might have a problem with "Effient," Eli Lilly's proposed name for its bloodthinner, because it was too close to efficient and all the connotations that would have.
A late upturn pushed stocks higher Wednesday as investors rotated into defensive stocks like pharmaceuticals and Alcoa advanced ahead of earnings.
Stocks turned lower Wednesday as investors got defensive ahead of earnings season, rotating into pharmaceuticals and out of techs.
The nation's hospitals will give up $155 billion in future Medicare and Medicaid payments to help defray the cost of President Barack Obama's health care plan, a concession the White House hopes will boost an overhaul effort that's hit a roadblock in Congress.
Stocks rebounded Wednesday after a major selloff in the previous session as earnings season gets into gear.
The historic budget crisis in California could go up in smoke if one organization has its way.
Futures indicated a slightly higher open for Wall Street Wednesday on profit taking after the major selloff the previous day.
This sector offers long-term growth, even in a slowdown. Even oil can’t promise that.
Perhaps reflecting concerns about the size and growth of the market for HPV shots and GSK's late entry, investors are not enthusiastic about the prestigious publication of the company's robust new test results. As I write this, GSK shares are the biggest percentage loser in big pharma.
Could a carrot-chomping Bugs Bunny become a drug pitchman? Well, maybe, if the small Israeli company Protalix BioTherapeutics could pay Warner Brothers enough money for Bugs' services.